Evidence also suggests that CD4 and CD8 T cells can act as biomarkers and therapeutic targets for breast cancer treatment [47, 48], which is in keeping with our finding that higher risk scores based on the eight-IRG signature were associated with higher levels of CD8 and resting CD4 memory T cells. Here, CD8A is linked to breast cancer.